key: cord-0845822-g457f9xa
authors: Sadasivam, Balakrishnan; Atal, Shubham; Ray, Avik; Sharma, Swati
title: The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19
date: 2020-08-27
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.08.058
sha: 5a0bedae749e463a0403bd388367c5c3feb3663d
doc_id: 845822
cord_uid: g457f9xa

nan

Monforte et al reports the findings from a cohort of 159 hospitalised patients with and shows that the effectiveness of hydroxychloroquine (HCQ) is higher for individuals with the milder form of the disease [1] . However, the authors have not mentioned the dose, frequency and duration of treatment with HCQ or any of the other medications received by the patients.

HCQ has been in use as an antimalarial since 1955. The universally recommended loading dose of HCQ for the management of uncomplicated malaria is 800 mg. It is noteworthy that in the dosing regimen of the HCQ arm in all the three major global trials -Solidarity, RECOVERY and DisCoVeRy, the recommended loading dose for treatment of COVID-19 was 1600 mg (2 oral loading doses of 800 mg each 6 hours apart) -exactly double of the antimalarial dose.

Notably, the HCQ arms in all of these trials have been discontinued [2-4]. But why is there a need for such a high loading dose?

For a drug with a large volume of distribution such as HCQ (5522 L) [5] , a high loading dose is required to achieve a plasma concentration above the minimum effective concentration Could this disparity in the loading dose have led to HCQ not meeting the desired efficacy endpoints in the unsuccessful trials? However, increasing the dose also compromises the safety, mainly related to cardiac conduction defects. The benefit to risk ratio were not found to be favourable for all the three aforementioned trials. Additionally, since the elimination half-life (t½) of HCQ is about 50 days [9] , the metabolites would remain for a prolonged period after such a high loading dose, compromising the safety profile even further. Moreover, the rationality for a continuous dosing regimen of HCQ in light of its long elimination half-life and the fact that the COVID-19 illness lasts for about 10 days for most persons [10] is debatable.

We therefore request the authors to share the entire dosing regimen of HCQ which was administered to the patients and ask for their opinion on whether it played any role in their findings of the effectiveness of HCQ for COVID-19.

J o u r n a l P r e -p r o o f

Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?

Recovery trial. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19

World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

Discovery: Stopping inclusions in two treatment groups

A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial

Bioavailability of hydroxychloroquine tablets in healthy volunteers

Duration of Isolation and Precautions for Adults with COVID-19